MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

✍ Scribed by Hu, Shimin; Xu-Monette, Zijun Y.; Wu, Lin; Visco, Carlo; Tzankov, Alexander; Montes-Moreno, Santiago; Dybkær, Karen; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L.; Hsi, Eric D.; Zhao, X. Frank; Choi, William W.L.; Zhao, Xiaoying; Zhang, Xiaohong; Han van Krieken, J.; Huang, Qing; Huh, Jooryung; Ai, Weiyun; Ponzoni, Maurilio A.; Ferreri, Andres J.M.; Zhou, Fan; Winter, Jane N.; Go, Ronald S.; Li, Yong; Piris, Miguel A.; Møller, Michael B.; Miranda, Roberto N.; Medeiros, L. Jeffrey; Young, Ken H.

• Book ID: 122285142
• Publisher: Elsevier
• Year: 2013
• Tongue: English
• Weight: 75 KB
• Volume: 13
• Category: Article
• ISSN: 2152-2650
• DOI: 10.1016/j.clml.2013.07.095